news 5 days ago

RDx BioScience Points to Physician Gap in Addiction Medicine, Urges More Physicians to Specialize in Treatment of Substance-Use Disorders

The Associated Press

KENILWORTH, N.J.--(BUSINESS WIRE)--Apr 15, 2019--In response to the U.S. surgeon general's estimate that more than 20 million  people have a substance-use disorder, RDx BioScience (RDx) highlights the urgent need for physicians with extensive clinical experience to specialize in addiction medicine to improve treatment and fill a gap in care to address the nation's growing drug overdose crisis.

“The opioid epidemic has underscored the impact of the physician shortage in this area, prompting medical institutions across the United States to create fellowships for physicians interested in treating substance-use disorders,” says Scott Howell, D.O., MPH &TM, CPE, chief medical officer, RDx. “Substance-use disorders must be treated with the same precision and science as other diseases, which is why RDx offers expertise in drug testing in addiction treatment settings. We provide a collaborative relationship and a high-quality lab for test panel selection, detecting sample tampering, interpreting test results, and regional drug use trends.”

In the past, addiction medicine has been the purview of psychiatry, but in 2015 the American Board of Medical Specialties (ACGME) began recognizing addiction medicine as a legitimate subspecialty, paving the way for physician training in this field. In 2018, ACGME began accrediting its first round of addiction medicine fellowship programs. Physicians can also turn to specialists to learn, for example, how to provide  medication-assisted treatment like  buprenorphine, which has been shown to  reduce the risk of death  among people who have recovered from an opioid overdose.

“Addiction treatment is a unique medical specialty, different than practices that focus on infectious or short-term disease, and it requires treatment programs and exceptional laboratory services to effectively address the nature of addiction and the needs of those who battle the opioid epidemic,” Howell adds, “RDx is committed to playing a role in helping individuals recover from drug abuse by directing the delivery of patient care using a high-technology laboratory to provide full-service diagnostics and genomic testing supported by evidence-based research.”

About RDx BioScience

RDx is a full-service, high-technology laboratory. We are fast, accurate, and deliver value-based service nationally. RDx is accredited by the  College of American Pathologists (CAP)  as a certified, full-service medical laboratory. Visit  http://www.rdxbioscience.com/

View source version on businesswire.com:https://www.businesswire.com/news/home/20190415005061/en/

CONTACT: Media:

CPR for RDx

Brittany Tedesco

btedesco@cpronline.com

201.641.1911 x14

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY

INDUSTRY KEYWORD: PRACTICE MANAGEMENT HEALTH ALTERNATIVE MEDICINE GENETICS HOSPITALS MENTAL HEALTH PHARMACEUTICAL

SOURCE: RDx BioScience

Copyright Business Wire 2019.

PUB: 04/15/2019 08:00 AM/DISC: 04/15/2019 08:00 AM

http://www.businesswire.com/news/home/20190415005061/en